Moderna Inc

MRNA: XNAS (USA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
LOCK|?zLOCK|mT@LOCK|d?!Zbk

Moderna: Failure of Cytomegalovirus Vaccine Further Increases Pressure on Oncology Pipeline

On Oct. 22, Moderna announced that its cytomegalovirus vaccine candidate mRNA-1647 failed to show significant efficacy in a phase 3 trial for congenital CMV. Shares fell 4% after hours.

Sponsor Center